Shots:

• iTeos to receive $625M up front & is eligible to receive up to ~$1.45B in milestone upon achievement of certain milestones & royalties on ex-US sales. Both companies will share global development costs of EOS-448 and co-commercialize & share profits in the US
• GSK to receive an exclusive license for commercialization (Ex-US) & access to Abs that target all 3 known CD226 checkpoints - TIGIT- CD96 & PVRIG
• EOS-448 is currently being evaluated in the P-I study for advanced solid tumors. The companies plan to initiate EOS-448 + dostarlimab in 2022 while GSK plans to submit an IND for GSK’562 in mid-2022

Ref: Globenewswire | Image: GSK